Entrada Therapeutics, Inc. - Common Stock (TRDA)

One major biotech investor just walked away from Viking Therapeutics. Here’s what the move may—and may not—mean for the company’s clinical-stage future.

A major biotech investor just walked away from MoonLake after a rough year for the stock. Here’s what that move signals—and what long-term investors should keep an eye on next.

Entrada Therapeutics (TRDA) missed Q2 2025 revenue and EPS estimates, posting $1.95M revenue vs. $9.84M expected and a $1.04 loss per share. Shares fell 2% pre-market amid investor concerns. Pipeline progress includes DMD trials and regulatory filings.

Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne muscular dystrophy patients.

TRDA stock results show that Entrada Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

TRDA stock results show that Entrada Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Although U.S. stocks closed lower on Wednesday, there were a few notable insider trades.

Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.

Entrada Therapeutics Inc (NASDAQ: TRDA) shares are trading lower after the company announced updates on ENTR-601-44 in 

Gainers Sera Prognostics, Inc. (NASDAQ: SERA) shares surged 63.4% to $2.11 after the company announced top-line data from the AVERT PRETERM TRIAL.

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 150 points on Tuesday.

Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 296% to $3.71 after the company announced interim results from the ICESECRET study for the treatment of patients with small renal masses who cannot be offered kidney-preserving surgery.